Chief Rabbi of Israel Affirms Aleph Farms’ Cultivated Steak is Kosher
19.1.2023 18:01:00 EET | Business Wire | Press release
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that Israeli Chief Rabbi, David Baruch Lau, has ruled its cultivated steak to be kosher, which means permitted for consumption by Jews under religious law. This ruling, coming from the leader of the Chief Rabbinate — a bellwether rabbinic council for religious certifications in Judaism — opens the door for Aleph Farms to receive a kosher certificate ahead of its market launch later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005570/en/
Cultivated thin cut steak by Aleph Farms (Photo: Business Wire)
“This ruling is meaningful not only for Aleph Farms as a company but also for the entire cultivated meat industry. It sets a foundation for an inclusive public discourse about the intersection of tradition and innovation in our society. At Aleph, we innovate in order to provide quality nutrition to anyone, anytime, anywhere in service of people and the planet, and that includes people with different culinary traditions,” said Didier Toubia, Co-Founder and CEO of Aleph Farms. “We’re excited that more groups of diners can enjoy our products regardless of their religion, helping us to advance our inclusive vision for food security and tap into different food cultures around the world”.
This ruling indicates an openness among religious authorities to certify cultivated meat products as appropriate to consume and paves the way forward as Aleph Farms works to get kosher certification for its production facility in Rehovot and its individual products. Aleph Farms is also in contact with Muslim, Hindu and other religious authorities to certify its products as a viable dietary option for groups that have different religious practices.
The global kosher beef market size is expected to reach approximately $100.85 billion USD by 2030. The growing preference for kosher beef in key countries such as the US, France and Israel, which have the highest Jewish populations and account for over 86% of the global Jewish population, is driving the market. In 2021, approximately 73.9% of Israel’s population was Jewish, making it a key market for kosher beef. This ruling indicates that upon market launch in Israel, expected in the near future, local authorities will likely confirm Aleph Farms cultivated steaks are kosher, enabling Jewish diners who observe kashrut to incorporate them into their diets.
Aleph Farms is working closely with regulatory agencies around the world as it prepares for the commercial launch of its first product, a cultivated thin-cut beef steak. The company also plans to produce different cuts of steak as well as cultivated collagen through additional proprietary capabilities. In all cases, Aleph Farms’ products are produced from starter cells that come from a fertilized egg, which was sourced from a premium Black Angus cow named Lucy – she lives on a breeding farm in California. From a one-time collection of Lucy’s fertilized egg, Aleph Farms can grow thousands of tons of cultivated meat without engineering or immortalizing cells, avoiding slaughter and acting as part of an inclusive solution for sustainable and secure food systems.
About Aleph Farms
Aleph Farms grows cultivated beef steaks from cells that are isolated from a living cow and not immortalized or genetically modified, avoiding slaughter and achieving reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub by Strauss Group, and Professor Shulamit Levenberg of the Technion - Israel Institute of Technology. Its vision is to ensure unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005570/en/
Contact information
Lizi Sprague
alephfarms@songuepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 09:07:00 EET | Press release
EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects our belief that trust in software must be engineered in the open," said Paul Sherwood, Codethink’s Chair
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
